Patents by Inventor Edward Halk
Edward Halk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9458236Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 16, 2013Date of Patent: October 4, 2016Assignee: GENMAB A/SInventors: Jan G. J. Van De Winkel, Marcus Antonius Van Dijk, Edward Halk, Arnout F. Gerritsen, Jørgen Petersen, Ole Baadsgaard
-
Publication number: 20140141006Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: October 16, 2013Publication date: May 22, 2014Applicant: GENMAB A/SInventors: Jan G. J. VAN DE WINKEL, Marcus Antonius VAN DIJK, Edward HALK, Arnout F. GERRITSEN, Jørgen PETERSEN, Ole BAADSGAARD
-
Patent number: 8586041Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: May 11, 2009Date of Patent: November 19, 2013Assignee: Genmab A/SInventors: Jan G. J. van de Winkel, Marcus Antonius van Dijk, Edward Halk, Arnout F. Gerritsen, Jorgen Petersen, Ole Baadsgaard
-
Patent number: 8580259Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.Type: GrantFiled: July 19, 2012Date of Patent: November 12, 2013Assignee: Medarex, L.L.C.Inventors: Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
-
Publication number: 20120288500Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.Type: ApplicationFiled: July 19, 2012Publication date: November 15, 2012Inventors: Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
-
Patent number: 8247537Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.Type: GrantFiled: November 15, 2007Date of Patent: August 21, 2012Assignee: Medarex, Inc.Inventors: Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
-
Publication number: 20100172900Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.Type: ApplicationFiled: November 15, 2007Publication date: July 8, 2010Inventors: Alan Korman, Mark Selby, Kent B. Thuduim, Edward Halk, Mohan Srinivasan, David B. Passmore
-
Publication number: 20100008929Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: May 11, 2009Publication date: January 14, 2010Applicant: GENMAB A/SInventors: Jan G. J. van de Winkel, Marcus A. van Dijk, Edward Halk, Arnout F. Gerritsen, Jorgen Petersen, Ole Baadsgaard
-
Patent number: 7595378Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: December 16, 2002Date of Patent: September 29, 2009Assignee: Genmab A/SInventors: Jan G. J. van de Winkel, Marcus A. van Dijk, Edward Halk, Arnout F. Gerritsen, Jørgen Petersen, Ole Baadsgaard
-
Patent number: 7247301Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: June 13, 2002Date of Patent: July 24, 2007Assignee: Genmab A/SInventors: Jan G. J. van de Winkel, Marcus A. van Dijk, Arnout F. Gerritsen, Edward Halk
-
Publication number: 20060037093Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: ApplicationFiled: September 30, 2005Publication date: February 16, 2006Applicants: Kirin Brewery Company Limited, Medarex, Inc.Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward Halk
-
Publication number: 20060026698Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.Type: ApplicationFiled: September 30, 2005Publication date: February 2, 2006Applicants: KIRIN BREWERY COMPANY LIMITED, Medarex, Inc.Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward Halk
-
Publication number: 20050201994Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.Type: ApplicationFiled: January 20, 2005Publication date: September 15, 2005Applicant: Medarex, Inc.Inventors: Alan Korman, Edward Halk, Nils Lonberg
-
Publication number: 20030194403Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: December 16, 2002Publication date: October 16, 2003Applicant: GENMAB, INC.Inventors: Jan G.J. van de Winkel, Marcus A. van Dijk, Edward Halk, Arnout F. Gerritsen, Jorgen Petersen, Ole Baadsgaard
-
Publication number: 20030091561Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: ApplicationFiled: June 13, 2002Publication date: May 15, 2003Applicant: GENMAB A/SInventors: Jan G.J. van de Winkel, Marcus A. van Dijk, Arnout F. Gerritsen, Edward Halk